Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Phase 4
Completed
- Conditions
- Meningococcal Infection
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2006-10-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 241
- Registration Number
- NCT00310635
- Locations
- 🇩🇪
Mainz, Kehl, Traunreut, Mühldorf am Inn, Bad Sobernheim, Bad Kreuznach, Baldham, Speyer,, Oppenheim,, Kempten, Germany
Persistence of Immune Response After Vaccination With MCC
Phase 4
Completed
- Conditions
- Prevention of Meningococcal Infection
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1244
- Registration Number
- NCT00310687
- Locations
- 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxfordshire, United Kingdom
Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS
Phase 3
Completed
- Conditions
- De Novo Renal Transplantation
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Novartis
- Target Recruit Count
- 119
- Registration Number
- NCT00308425
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
Phase 4
Completed
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00305903
Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1288
- Registration Number
- NCT00304226
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder
Phase 3
Completed
- Conditions
- ADHD, ADD
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 252
- Registration Number
- NCT00301236
- Locations
- 🇺🇸
Novartis Investigational Site, Houston, Texas, United States
A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00300287
SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 40
- Registration Number
- NCT00299832
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Japan, Japan
SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 39
- Registration Number
- NCT00299806
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Japan, Japan
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 976
- Registration Number
- NCT00294710
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States